Host Ben Synth examines why 68% of patients discontinue Ozempic or Wegovy within one year, exploring cost barriers, side effects, dosing gaps, and metabolic plateaus driving mass discontinuation. Covers real-world adherence data showing weight regain after stopping, financial obstacles, and systemic failures underlying the GLP-1 dropout crisis.
Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV
This content was created in partnership and with the help of Artificial Intelligence AI
Show More
Show Less
27 mins